United Kingdom Breast Cancer Therapeutics Market to be Dominated by Targeted Therapy through 2028
increasing prevalence of breast cancer and changing lifestyle
are expected to drive the United Kingdom Breast Cancer Therapeutics Market in
the forecast period, 2024-2028.
According to TechSci Research report, “United Kingdom Breast Cancer Therapeutics Market – By
Region, Competition Forecast and Opportunities, 2018-2028,” the United
Kingdom Breast Cancer Therapeutics Market is projected to experience
substantial growth during the forecast period of 2024-2028. The market for
breast cancer therapeutics is witnessing significant expansion, driven by the
increasing prevalence of breast cancer and growing investments in healthcare
research and innovation. Notably, the rising obesity rates in the United
Kingdom contribute to an elevated risk of breast cancer, as obesity affects
hormone levels, specifically leading to increased estrogen production, which is
associated with hormone receptor-positive breast cancer development.
Consequently, the mounting prevalence of obesity underscores the urgent
requirement for innovative therapeutics tailored to obese patients, considering
their distinct physiological characteristics and treatment responses. Moreover,
alcohol consumption has been linked to an increased risk of breast cancer and
given the significant drinking culture in the United Kingdom, addressing the
harmful use of alcohol is crucial in mitigating the burden of breast cancer.
Alcohol can disrupt hormone levels, impair DNA repair mechanisms, and promote
oxidative stress, all contributing to the development of breast cancer.
Therefore, addressing alcohol-related breast cancer risk necessitates public
health initiatives to raise awareness and promote responsible alcohol
consumption, as well as the development of targeted therapies. The interplay
between age, obesity, alcohol misuse, and family history of breast cancer
shapes the landscape of breast cancer therapeutics in the United Kingdom. To
improve prevention, diagnosis, and treatment, a comprehensive approach is
required, including the development of targeted therapeutics tailored to
specific patient profiles based on age, body composition, alcohol consumption
patterns, and genetic predisposition. Nonetheless, challenges persist, such as
high treatment costs, access disparities, and the ongoing need for research and
development. Ensuring equitable access to state-of-the-art treatments and
addressing healthcare disparities are crucial aspects that must be tackled to
enhance breast cancer outcomes for all patients in the United Kingdom, which
may impact the market's growth in the forecast period.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on “United Kingdom Breast Cancer Therapeutics Market “.
The United Kingdom Breast Cancer Therapeutics
Market is categorized into Therapy, End User, Region and Competitive Landscape.
Regarding Therapy, the market is segmented into
Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, and Others Chemotherapy
are projected to experience growth during the forecast period. These treatments
for breast cancer often exhibit fewer side effects as they specifically target
the abnormalities in cancer cells, sparing healthy, normal cells. These
therapies focus on specific regions within or on the tumor cells. While
targeted therapies may not be suitable for all breast cancer patients, which is
expected to contribute to market growth in the future.
In terms of End User, the market is divided into
Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. The
hospitals segment is anticipated to witness growth in the forecast period due
to the availability of advanced facilities for both in-patient and out-patient
treatments, as well as diagnostic services. Furthermore, the presence of
skilled healthcare professionals in hospitals is contributing to the expansion
of the United Kingdom Breast Cancer Therapeutics Market.
Major
companies operating in the United Kingdom Breast Cancer Therapeutics Market are:
- Novartis AG
- Pfizer Inc
- Eli Lilly & Company
- Merck Co. & Inc.
- GlaxoSmithKline, Plc.
- AstraZeneca Plc
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Sanofi S.A.
- Mylan NV
Download Free Sample Report
Customers can also request
10% free customization in this report.
“The United Kingdom Breast Cancer Therapeutics
Market is poised to experience significant growth in the coming years. This is
attributed to the rising prevalence of breast cancer cases in the country,
primarily due to the aging population and changing lifestyles of women. The
market will be driven by increasing healthcare expenditure and government
initiatives focused on research and innovation. Additionally, the adoption of
revolutionary technological advancements in the medical therapeutics industry
and the expansion of hospitals and healthcare professionals in the nation will
further bolster market growth. It is anticipated that the market will continue
to grow through 2028,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based global management consulting firm.
“United
Kingdom Breast Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy,
Immunotherapy, Targeted Therapy, Others), By End User (Hospitals, Specialty
Clinics, Ambulatory Surgical Centers, Others), By
Region, Competition Forecast & Opportunities,
2018-2028F,” has evaluated the future growth potential of United Kingdom Breast
Cancer Therapeutics Market and provides statistics & information on market
size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in the United Kingdom
Breast Cancer Therapeutics Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com